## Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Issue Date:

ARF No: CBE/ARF/000 3

PART A: To be completed by the	Receiv	er (a separate	form must be	completed for e	each sample	type)		
A1. Details of Sample/Specimen	)							
Type/ID: (eg primary cell, cell line, tisso fluid, excreta, biological agent)	ie, body	Haematopoietic Cell based Therapies				⊠ Human □ Animal		
Format / Quantity: (eg vials, slides, o	etc)	4x50mL tube containing 20mL ficol unit						
Tissue site/Organ source:		Cord Blood		□N/A				
Batch N°:		9 9 8	90	a *	n n			
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)?  If No, go to section A2.							⊠Yes □No	
Is the material obtained from an	HTA lice	enced Tissue B	ank with REC a	pproval for gene	eric researcl	n use?	`⊠Yes □No	
Is the material obtained for storage and use under a project specific NHS REC approval?								
Is the material licensable under the HTA? Indicate source below:							⊠Yes □No	
	Commer	cial Supplier	☐ Imported (fro	om outside Engl	and, Wales	or N.Ireland)	n n	
			Assigned Unique ID 2 x cryovial containing 7.575 e6 cells S00113506 and S00					
If Yes, provide Project Ref N°:		BRA060 & BRA010						
If Yes, provide the name of the PI:  Dr Rob Thon			nas					
A2. Details of Receipt								
Date/Time of receipt		Date	19/07/2018		Time:			
ID of Receiver		Name:	Jon Harriman		Dept:	CBE		
ID of Supplier/Provider		Name:	Anthony Nolan		Country:	UK		
PART B: To be completed by the	Receive	er						
B1. Inspection and Quarantine								
Has a biological risk assessment for the use of this material been approved?			⊠Yes □No	Ref Number: BRA060 & BRA010				
Physical integrity of the material	otable?	⊠Yes □No	If No, describe action taken					
Quantity received correct?			⊠Yes □No	If No, describe action taken				
Labelling correct and legible?			⊠Yes □No	If No, describe action taken				
attached to this form?				⊠Yes □No □N/A				
If No, add reference or details	mater	agreements to enable transfer of naterial eg MTA, SLA Details/evidence/assurance of		⊠Yes □No □N/A      ⊠Yes □No □N/A				
to ensure traceability	conse	nt		300 101 101 101 101 101 101 101 101 101	565			

	Other (describe	Yes \( \text{No} \( \text{N/A} \)		, , ,	
	Building/Room		CBE H19 Cold store & once processed will be stored in - 80 overnight and transferred to Liquid N2 - Bank 7 Rack 5		
Temporary storage - Quarantine location (as applicable)	Storage Unit ID Within storage Date/Time of q	unit location ID	7 R5 Bx A2- S00113507		
Submitted by:	Signature:		Date: 20/07/2018		
PART C: To be completed by the	departmental Q	uality Manager			
C1. Quality Assurance Checks					
Has the sample/specimen been s	☑Yes □No □N/A				
Has the donor been screened for	☑Ýes □No □N/A				
Has the sample/specimen been s	☑Yes □No □N/A				
Is there evidence that the supplie	☑Yes □No □N/A				
or other recognised certification?  For HTA licensable material, is the and use of the material under the	⊠Ýes □No □N/A				
Is there sufficient evidence to sup	□Yes ੴNo □N/A				
C2. Approval for release from qu	arantine				
Can the material be released from released for processing?	n quarantine and	transferred to desi	gnated storage area or	☑Ýes □No	
If No, provide recommendations for deposition of the material and the results of any action		☐Accept as is, b	ut with extra controls		
		☐Rework or rep specified require	rocess to meet the ments		
		☐Test to meet s	pecified requirements		
relating to non-conforming mate	IIGI.	☐Return to supp	olier/provider		
		□Disposal			
	Building/Room  Storage Unit ID				
If Yes, provide details of storage applicable)	ocation (as	Within storage unit location ID		BY (NS DXAI+HZ	
		Database Reference			
		Date/Time of transfer			
Approved by:		Signature:	col	Date: (3/8/17	